Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Sickle Cell Anemia
Interventions
DRUG

Hydroxyurea

OTHER

Placebo

Trial Locations (1)

20010

Children's National Medical Center, Washington D.C.

All Listed Sponsors
lead

Children's National Research Institute

OTHER

NCT02090296 - Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study | Biotech Hunter | Biotech Hunter